What is ivonescimab and why is outperforming Keytruda significant?

Ivonescimab is a bispecific antibody — a single engineered antibody that simultaneously binds two different molecular targets. Ivonescimab's two targets: PD-1 (Programmed Death-1) — a checkpoint protein on immune T cells; blocking PD-1 prevents tumors from suppressing the immune response; PD-1/PD-L1 inhibitors (pembrolizumab/Keytruda, nivolumab/Opdivo, atezolizumab/Tecentriq) have revolutionized cancer treatment and generate tens of billions in annual sales. VEGF (Vascular Endothelial Growth Factor) — a protein that stimulates tumor blood vessel formation (angiogenesis); anti-VEGF drugs (bevacizumab/Avastin, ramucirumab/Cyramza) reduce tumor blood supply; combining anti-VEGF with checkpoint inhibitors has shown synergistic activity in several cancers. Why Keytruda is the benchmark: Keytruda (pembrolizumab) by Merck is the world's best-selling cancer drug (~$25B annual revenue); it's the standard-of-care first-line treatment for PD-L1-high (TPS ≥50%) non-small cell lung cancer; no drug has previously demonstrated superiority to Keytruda in head-to-head randomized trials in this setting. Why ivonescimab's data is significant: the HARMONi-2 trial in China compared ivonescimab vs. pembrolizumab in PD-L1 high NSCLC; ivonescimab achieved median PFS of approximately 11.1 months vs. 5.8 months for pembrolizumab (hazard ratio 0.51 — meaning 49% reduction in risk of progression or death); if replicated globally, this would establish ivonescimab as a potential new standard of care for the most common and deadly cancer globally.

What is an exon-skipping drug and why does Sarepta have multiple approved DMD products?

Exon skipping is a genetic medicine approach that corrects the reading frame of the dystrophin gene mRNA, allowing a truncated but partially functional dystrophin protein to be produced. Sarepta's exon-skipping platform: different DMD mutations affect different exons (gene segments); Sarepta has developed antisense oligonucleotides (ASOs) that 'skip' a specific exon to restore the reading frame. Different exons require different drugs: Eteplirsen (Exondys 51) — skips exon 51; treats approximately 13% of DMD patients. Golodirsen (Vyondys 53) — skips exon 53; treats approximately 8% of DMD patients. Casimersen (Amondys 45) — skips exon 45; treats approximately 8% of DMD patients. Viltolarsen (Viltepso) — another exon 53 skipping drug. In total, exon-skipping drugs address approximately 30% of DMD patients (those with specific mutation patterns amenable to exon skipping). Why this matters: Sarepta's multiple approved exon-skipping drugs create a comprehensive DMD franchise; the drugs are given weekly IV infusions or subcutaneous injections; while their functional benefit has been debated (limited improvement in motor function in some trials), they represent the first disease-modifying therapies for many DMD patients; combined with Elevidys, Sarepta addresses the largest addressable DMD patient population.

What are the key differences between checkpoint inhibitors and bispecific antibodies in cancer?

Checkpoint inhibitors release the 'brake' that tumors put on immune cells: immune T cells have checkpoint proteins (PD-1, CTLA-4) that prevent autoimmune attack on normal tissues; tumors exploit this by expressing checkpoint ligands (PD-L1) that engage these brakes, hiding from immune surveillance; checkpoint inhibitor drugs (Keytruda, Opdivo) block these checkpoint interactions, allowing T cells to recognize and attack tumor cells; checkpoint inhibitors work best in tumors with high mutation burden (many abnormal proteins for immune cells to recognize) and high PD-L1 expression. Bispecific antibodies target two different antigens simultaneously with a single molecule: traditional antibodies target one antigen; bispecific antibodies are engineered to bind two different targets; the combination in ivonescimab (PD-1 + VEGF) may achieve synergy: anti-VEGF reduces immunosuppressive effects of tumor vasculature and may improve T cell infiltration into the tumor; PD-1 blockade prevents T cell exhaustion once cells reach the tumor; combining both targets in one molecule may achieve better spatial co-localization and more coordinated anti-tumor activity than using two separate drugs. The bispecific antibody field: bispecific antibodies have become a major oncology drug class (Teclistamab for myeloma, mosunetuzumab for lymphoma, blinatumomab for leukemia all target CD3 on T cells + a tumor antigen — 'T cell engagers'); ivonescimab is different from T cell engagers — it combines two solid tumor microenvironment targets.

brimindinvest.com / compare / srpt-vs-smmtLIVE

SRPT

Sarepta Therapeutics, Inc. · Healthcare - Rare Disease Gene Therapy

$17.53

+5.35% this month

VERSUS

⟷

COMPARE

SMMT

Summit Therapeutics Inc. · Healthcare - Clinical-Stage Oncology

$13.75

-13.25% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

SRPT

1

SMMT

3

SMMT LEADS 3/5

Comparison scoreboard

SMMT LEADS 3/5

AI Score

SRPT 24.7

SMMT ✓30.7

1Y Return

SRPT ✓-15.60%

SMMT -31.80%

Fwd P/E

SRPT 6.43

SMMT ✓-15.61

Target Up.

SRPT +25.50%

SMMT ✓+104.87%

Op. Margin

SRPT N/A

SMMT N/A

Metrics last refreshed: 6/20/2026

Quick take

SRPT vs SMMT Stock Comparison: AI Score, Valuation, Performance and Upside

SRPT (Sarepta Therapeutics) and SMMT (Summit Therapeutics) are both at key inflection points in rare disease and oncology — Sarepta has an approved DMD gene therapy (Elevidys) and multiple exon-skipping drugs generating revenue while navigating label expansion, while Summit is clinical-stage with ivonescimab potentially being the first drug to outperform Merck's Keytruda in lung cancer if global trial data confirms Chinese Phase 3 results. Sarepta has established revenue; Summit has binary transformative upside.

SRPT vs SMMT is commercial rare disease gene therapy leader in DMD with proven exon-skipping franchise (Sarepta's Elevidys gene therapy and multiple exon-skipping drugs generating revenue in the Duchenne muscular dystrophy market, with label expansion as the near-term catalyst) versus clinical-stage oncology company with potentially transformative bispecific antibody data in non-small cell lung cancer (Summit's ivonescimab showing superiority over Keytruda in Chinese Phase 3 trials, pending global confirmatory data that could unlock the world's largest oncology opportunity) — commercial rare disease execution versus binary oncology development bet.

Live analysis · updated 6/20/2026

SMMT holds the edge across 3 of 5 key metrics in this comparison. SRPT has delivered stronger 1-year price return (-15.60% vs -31.80%), though SMMT trades at the lower forward P/E (-15.61x vs 6.43x). Analyst consensus implies meaningfully more upside for SMMT (+104.87%) than for SRPT (+25.50%).

Normalized 1Y performance

SRPT

SMMT

Recent returns

SRPT

SMMT

Analyst price targets & sentiment

SRPT · 23 analysts

STRONG BUYHOLDSTRONG SELL

Hold (2.8/5.0)

Price target range

analyst low$5.00
analyst high$38.00
analyst mean$22.00
current price$17.53

+25.5% upside to analyst mean

SMMT · 13 analysts

STRONG BUYHOLDSTRONG SELL

Buy (2.0/5.0)

Price target range

analyst low$7.61
analyst high$44.21
analyst mean$28.17
current price$13.75

+104.9% upside to analyst mean

Who should consider this stock?

SRPT may suit investors who:

→Want rare disease biopharmaceutical exposure with established revenue from DMD gene therapy and exon-skipping products, reducing pure clinical binary risk
→Believe Elevidys gene therapy will receive full label expansion (to all DMD patients, potentially), dramatically expanding the addressable patient population and commercial revenue
→Value Sarepta's comprehensive DMD portfolio and manufacturing investment as creating a durable competitive position in rare muscle disease that would be difficult for competitors to replicate

SMMT may suit investors who:

→See ivonescimab's Phase 3 data as a genuine scientific signal that bispecific PD-1/VEGF inhibition outperforms checkpoint inhibition alone in NSCLC, with global trial confirmation being the key remaining binary event
→Are comfortable with clinical binary risk in exchange for exposure to potentially the first drug to outperform Keytruda in lung cancer — a commercial opportunity in the world's largest oncology market
→Believe the HARMONi-2 data's magnitude (ivonescimab more than doubling PFS versus Keytruda) is too large to be explainable by chance or ethnic population differences, increasing confidence in global trial success

Performance & AI score

Metric	SRPT	SMMT
AI score	24.7	30.7
AI rank	#3030	#2233
Latest close	$17.53	$13.75
1M return	+5.35%	-13.25%
6M return	-17.08%	-19.17%
1Y return	-15.60%	-31.80%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	SRPT	SMMT
1Y ago	$8.44K (-15.6%) started 2025-06-18	$6.82K (-31.8%) started 2025-06-18
5Y ago	$2.21K (-77.9%) started 2021-06-18	$20.8K (+108.0%) started 2021-06-18
10Y ago	$9.82K (-1.8%) started 2016-06-20	$17.7K (+77.0%) started 2016-06-20

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	SRPT	SMMT
Market cap	$1.85B	$10.67B
Trailing P/E	50.09	N/A
Forward P/E	6.43	-15.61
Price/Sales	0.85	15031.32
EV/Revenue	0.94	N/A
Analyst target	$22.00	$28.17
Target upside	+25.50%	+104.87%

Growth, profitability & risk

Metric	SRPT	SMMT
Revenue growth	-1.90%	N/A
Earnings growth	N/A	N/A
EPS growth	N/A	N/A
FCF margin	+9.38%	N/A
Operating margin	N/A	N/A
Profit margin	2.98%	0.00%
ROIC proxy	4.91%	-270.95%
Return on equity	4.91%	-270.95%
Dividend yield	0.00%	0.00%
Beta	0.20	-1.31
Debt/equity	69.57	3.67
Current ratio	4.63	7.41
Quick ratio	2.41	7.19

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

SRPT max drawdown45.70%

SMMT max drawdown55.49%

SRPT max wkly drop41.37%

SMMT max wkly drop27.10%

5Y risk snapshot

SRPT max drawdown92.72%

SMMT max drawdown91.78%

SRPT max wkly drop47.84%

SMMT max wkly drop47.36%

10Y risk snapshot

SRPT max drawdown93.33%

SMMT max drawdown95.75%

SRPT max wkly drop51.73%

SMMT max wkly drop82.17%

Performance metrics by period

Period	Metric	SRPT	SMMT
1Y	Growth	-15.60%	-31.80%
	CAGR	-15.61%	-31.81%
	Sharpe ratio	0.27	-0.18
	Max drawdown	45.70%	55.49%
	Max daily drop	35.91%	25.15%
	Max wkly drop	41.37%	27.10%
5Y	Growth	-77.91%	+108.02%
	CAGR	-26.07%	+15.78%
	Sharpe ratio	-0.13	0.62
	Max drawdown	92.72%	91.78%
	Max daily drop	42.12%	47.99%
	Max wkly drop	47.84%	47.36%
10Y	Growth	-1.79%	+76.96%
	CAGR	-0.18%	+5.88%
	Sharpe ratio	0.29	0.53
	Max drawdown	93.33%	95.75%
	Max daily drop	51.29%	79.84%
	Max wkly drop	51.73%	82.17%

Business comparison

Category	SRPT	SMMT
Company	Sarepta Therapeutics, Inc.	Summit Therapeutics Inc.
Sector	Healthcare - Rare Disease Gene Therapy	Healthcare - Clinical-Stage Oncology
Industry	N/A	N/A
Core business	Sarepta Therapeutics is a commercial-stage rare disease biopharmaceutical company focused primarily on Duchenne muscular dystrophy (DMD), a fatal genetic muscle-wasting disease affecting approximately 1 in 3,500 male births. Sarepta's approved products include Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy providing a functional copy of a shortened dystrophin gene approved for DMD patients aged 4-5 years (with broader approval under review), and exon-skipping drugs eteplirsen (Exondys 51), golodirsen (Vyondys 53), casimersen (Amondys 45), and viltolarsen (Viltepso) approved for specific DMD mutation subsets. Sarepta's DMD franchise provides the most comprehensive rare muscle disease portfolio of any company.	Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab (SMT112), a novel bispecific antibody combining PD-1 checkpoint inhibitor and VEGF (vascular endothelial growth factor) targeting into a single molecule for cancer treatment. Summit in-licensed ivonescimab from Akeso Biotech (a Chinese biotechnology company). Ivonescimab's mechanism: the PD-1 component blocks the checkpoint that tumors use to evade immune detection; the VEGF component reduces tumor blood vessel growth (anti-angiogenesis); combining both into one bispecific antibody aims to achieve synergistic anti-tumor activity. Summit has announced compelling Phase 3 data showing ivonescimab outperforming pembrolizumab (Keytruda — Merck's blockbuster PD-1 inhibitor) in non-small cell lung cancer.
Investor focus	Investors track Elevidys gene therapy label expansion (potentially to all DMD patients), real-world functional outcome data from Elevidys-treated patients, and the long-term commercial revenue trajectory of the DMD portfolio as gene therapy pricing is established.	Investors track Summit's ivonescimab Phase 3 trial data (the pivotal results showing superiority to Keytruda in PD-L1 high NSCLC), FDA regulatory process for ivonescimab BLA submission, and commercial launch preparation for what could be a blockbuster lung cancer drug.

SRPT strengths

→Elevidys represents a landmark gene therapy for DMD — gene therapy has the potential to provide long-lasting or potentially curative benefit from a single treatment; if Elevidys durably preserves motor function in DMD patients, it is transformative medicine with significant willingness-to-pay
→Comprehensive DMD franchise provides multiple revenue streams — Sarepta's exon-skipping drugs (Exondys 51, Vyondys 53, etc.) address approximately 30% of DMD patients eligible for exon-skipping; combined with Elevidys, Sarepta addresses the largest addressable DMD patient population of any company
→First-mover advantage in DMD gene therapy with significant manufacturing and regulatory expertise — Sarepta has invested heavily in AAV gene therapy manufacturing capability; gene therapy manufacturing expertise is a significant barrier to entry for competitors

SMMT strengths

→Ivonescimab Phase 3 data showed statistically significant superiority over pembrolizumab (Keytruda) — the HARMONi-2 trial in China (PD-L1 high NSCLC) demonstrated ivonescimab more than doubled progression-free survival (PFS) versus Keytruda; if confirmed globally, this would be the first drug in decades to outperform Keytruda in a head-to-head lung cancer trial
→Bispecific antibody mechanism may provide synergistic benefit versus combining separate PD-1 and anti-VEGF drugs — the single bispecific molecule may achieve better tumor penetration and synchronized activity than sequential administration of checkpoint inhibitors and anti-angiogenics
→Non-small cell lung cancer is the world's largest oncology market — NSCLC is the most common cancer globally; Keytruda generates approximately $25B in annual sales largely from lung cancer; a drug demonstrating superiority to Keytruda would be a transformative commercial opportunity

Risks to watch — SRPT

→Elevidys long-term durability data is critical — if the functional benefits of Elevidys diminish over time (as AAV gene therapy efficacy can wane if transgene expression declines), the gene therapy's value proposition is materially undermined
→High gene therapy pricing creates payer and access friction — Elevidys is priced at approximately $3.2 million per treatment; navigating insurance coverage, payer outcomes-based agreements, and patient access programs at this price point is complex
→FDA regulatory uncertainty around gene therapy efficacy standards — Elevidys received accelerated approval with ongoing confirmatory trial requirements; if confirmatory data doesn't demonstrate the functional improvement endpoints required by the FDA, label changes or withdrawal risk exists

Risks to watch — SMMT

→Global confirmatory trials are needed — the positive data from HARMONi-2 was conducted in China; Western regulators (FDA, EMA) typically require data from ethnically diverse global populations for full approval; the ongoing global HARMONi-A trial is the key risk
→Akeso relationship and intellectual property structure create complexity — Summit licensed ivonescimab from Akeso; Summit has rights for commercial territories outside China; the partnership structure and IP landscape will affect Summit's ability to commercialize
→Binary risk on global trial outcome — if HARMONi-A (global Phase 3 trial) does not replicate the HARMONi-2 PFS superiority versus Keytruda, Summit's entire investment thesis collapses

Frequently asked questions

Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic disease affecting primarily males (approximately 1 in 3,500 male births). DMD is caused by mutations in the dystrophin gene — the largest gene in the human genome — that result in the complete absence of functional dystrophin protein. Dystrophin's role: dystrophin is a structural protein that connects the cytoskeleton of muscle fibers to the surrounding extracellular matrix, protecting muscle cells from damage during contraction. Without dystrophin: muscle fibers are damaged during normal physical activity; damaged fibers trigger inflammation and fibrosis (scar tissue); this progressive muscle degeneration leads to loss of walking ability (typically by age 12-13), respiratory failure, and cardiomyopathy; median life expectancy without treatment is 25-30 years. Elevidys mechanism: Elevidys is an AAV (adeno-associated virus) gene therapy delivering a 'microdystrophin' gene — a shortened but functional version of the dystrophin gene (the full gene is too large to package in a viral vector); the microdystrophin provides some structural support for muscle fibers; Elevidys is administered as a single intravenous infusion; the goal is to preserve motor function, slow disease progression, and extend functional ambulation.

AI Prediction SignalNext 5 trading days

Members only

SRPT

+2.8%BUY

SMMT

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons

SRPT vs BMRN

Gene Therapy Leaders for Rare Muscle Disease